In patients with SSc that underwent autologous hematopoietic stem cell transplantation (aHSCT), a peak in the percentage of CD38++/CD10+/IgD+ transitional B cells and CD38++/CD27++/IgD−plasmablasts has been observed already one month after the procedure. This evidence concerns the gene CD38 and systemic sclerosis.